Herpes Zoster Not Linked to Increased Dementia Risk
Herpes zoster is not associated with increased dementia risk and may be associated with a small decrease in risk.
Herpes zoster is not associated with increased dementia risk and may be associated with a small decrease in risk.
The immunogenicity of low dose VZV vaccine delivered into the outer layers of skin compared with the standard dose delivered conventionally is investigated.
For adults aged 50 years or older, those with a COVID-19 diagnosis have an increased risk for developing herpes zoster.
Researchers sought to demonstrate real-world evidence of the effectiveness of baricitinib in patients with atopic dermatitis (AD).
Cutaneous manifestations after COVID-19 vaccination are recorded and reported by researchers.
The relationship between mRNA COVID-19 vaccination and varicella zoster virus vaccination are assessed.
The recommendation was based on data from clinical studies that assessed Shingrix in adults who previously had an autologous hematopoietic stem cell transplant and in those undergoing treatment for hematologic malignancies.
Event and incidence rates of herpes zoster in patients with RA treated with biologic, tsDMARDs are compared.
Clinical characteristics and features of herpes zoster infection may effectively identify patients more likely to have medication-resistant pain.
The safety and efficacy of upadacitinib vs dupilumab in adults with atopic dermatitis is assessed.